{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:13:43Z","timestamp":1769638423591,"version":"3.49.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:sec><jats:title>Background and purpose<\/jats:title><jats:p>Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare inflammatory demyelinating disorder of the central nervous system, frequently resulting in irreversible neurological deficits such as blindness and paralysis. Emerging evidence suggests that dyslipidemia is associated with increased disability and poorer outcomes in autoimmune diseases. The purpose of the study is to investigate the associations between lipid profile with neurological impairment and relapse.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study retrospectively collected data from 130 hospitalized patients with AQP4-IgG positive NMOSD. Based on the Expanded Disability Status Scale (EDSS) scores at admission, patients were categorized into a mild-to-moderate group (EDSS \u2264 5.5) and a severe group (EDSS \u2265 6). All included patients were followed for at least 1\u202fyear, and were further divided into relapse and non-relapse groups based on whether a relapse occurred during the follow-up period. Logistic regression analysis was used to identify independent risk factors associated with the severity of neurological impairment and relapse. Receiver operating characteristic (ROC) curve analysis was conducted to determine the cutoff value of apolipoprotein A-I (ApoA-I) in predicting severe neurological impairment. Spearman correlation analysis was performed to assess the relationships among ApoA-I, high-density lipoprotein cholesterol (HDL-C) and CRP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Multivariate binary logistic regression analysis revealed that ApoA-I (OR\u202f=\u202f0.138, 95% CI: 0.021\u20130.902, <jats:italic>p<\/jats:italic>\u202f=\u202f0.039) and the number of spinal cord lesion segments (OR\u202f=\u202f1.368, 95% CI: 1.181\u20131.584, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001) were independent risk factors for the severity of neurological impairment. The area under the ROC curve (AUC) for ApoA-I in predicting the severity of neurological impairment was 0.647 (95% CI: 0.542\u20130.751), with a cutoff value of 1.165, a sensitivity of 59.4%, and a specificity of 67.6%. Multivariate logistic regression analysis identified HDL-C (OR\u202f=\u202f0.082, 95% CI: 0.008\u20130.847, <jats:italic>p<\/jats:italic> =\u202f0.036), clinical phenotype\u2014specifically, compared to optic neuritis, myelitis (OR\u202f=\u202f0.130, 95% CI: 0.037\u20130.458, <jats:italic>p<\/jats:italic> =\u202f0.002), brainstem\/cerebral syndrome (OR\u202f=\u202f0.070, 95% CI: 0.007\u20130.731, <jats:italic>p<\/jats:italic> =\u202f0.026), and mixed phenotypes (OR\u202f=\u202f0.107, 95% CI: 0.018\u20130.642, <jats:italic>p<\/jats:italic> =\u202f0.014) \u2014as well as the use of subsequent monoclonal antibody therapy (OR\u202f=\u202f0.190, 95% CI: 0.045\u20130.799, <jats:italic>p<\/jats:italic> =\u202f0.023) as independent protective factors against relapse. Spearman correlation analysis showed that ApoA-I and HDL-C were significantly negatively correlated with CRP (<jats:italic>r<\/jats:italic>\u202f=\u202f\u22120.230, <jats:italic>p<\/jats:italic>\u202f=\u202f0.008; <jats:italic>r<\/jats:italic>\u202f=\u202f\u22120.310, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Reduced levels of ApoA-I and HDL-C were associated with more severe neurological deficits and an increased risk of relapse.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnins.2025.1629357","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T05:25:08Z","timestamp":1752557108000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Prediction of apolipoprotein A-I and high-density lipoprotein cholesterol in the neurological impairment and relapse of neuromyelitis optica spectrum disorder"],"prefix":"10.3389","volume":"19","author":[{"given":"Yanyan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziling","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baojie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rujia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shougang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jns.2017.11.022","article-title":"Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica","volume":"384","author":"Ajmera","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"101981","DOI":"10.1016\/j.msard.2020.101981","article-title":"Low high-density lipoprotein cholesterol and high triglycerides lipid profile in neuromyelitis optica spectrum disorder: associations with disease activity and disability","volume":"40","author":"Cho","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s13760-021-01712-3","article-title":"Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort","volume":"122","author":"Dauby","year":"2022","journal-title":"Acta Neurol. Belg."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"8227","DOI":"10.2147\/jir.S489723","article-title":"Serum low-density lipoprotein cholesterol levels are associated with relapse in Neuromyelitis Optica Spectrum disorder","volume":"17","author":"Ding","year":"2024","journal-title":"J. Inflamm. Res."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1038\/s41467-018-04332-3","article-title":"A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica","volume":"9","author":"Estrada","year":"2018","journal-title":"Nat. Commun."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1194\/jlr.M060970","article-title":"Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients","volume":"56","author":"Fellows","year":"2015","journal-title":"J. Lipid Res."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of Neuromyelitis Optica Spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front. Neurol."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"117120","DOI":"10.1016\/j.jns.2020.117120","article-title":"High density lipoprotein cholesterol and apolipoprotein A-I are associated with greater cerebral perfusion in multiple sclerosis","volume":"418","author":"Jakimovski","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1177\/13524585211024978","article-title":"Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder","volume":"28","author":"Kim","year":"2022","journal-title":"Mult. Scler."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.2147\/jir.S496018","article-title":"Serum lipid biomarkers for the diagnosis and monitoring of Neuromyelitis Optica Spectrum disorder: towards improved clinical management","volume":"18","author":"Li","year":"2025","journal-title":"J. Inflamm. Res."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bpa.12099","article-title":"The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica","volume":"24","author":"Lucchinetti","year":"2014","journal-title":"Brain Pathol."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1152\/physrev.00021.2023","article-title":"Glucocorticoids, their uses, sexual dimorphisms, and diseases: new concepts, mechanisms, and discoveries","volume":"104","author":"Martinez","year":"2024","journal-title":"Physiol. Rev."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jacl.2020.07.001","article-title":"Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis","volume":"14","author":"McComb","year":"2020","journal-title":"J. Clin. Lipidol."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.devcel.2021.03.034","article-title":"Lipid metabolism and lipid signals in aging and longevity","volume":"56","author":"Mutlu","year":"2021","journal-title":"Dev. Cell"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2011.06.045","article-title":"Emerging role of high density lipoproteins as a player in the immune system","volume":"220","author":"Norata","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12944-020-01221-x","article-title":"Lipoprotein profiling in early multiple sclerosis patients: effect of chronic inflammation?","volume":"19","author":"R\u00e1dikov\u00e1","year":"2020","journal-title":"Lipids Health Dis."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12974-021-02138-7","article-title":"Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder","volume":"18","author":"Schindler","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1152\/physrev.00031.2018","article-title":"Myelin in the central nervous system: structure, function, and pathology","volume":"99","author":"Stadelmann","year":"2019","journal-title":"Physiol. Rev."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1417270","DOI":"10.3389\/fimmu.2024.1417270","article-title":"Anti-inflammatory mechanism of apolipoprotein A-I","volume":"15","author":"Tao","year":"2024","journal-title":"Front. Immunol."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"100021","DOI":"10.1016\/j.lanwpc.2020.100021","article-title":"Incidence of neuromyelitis optica spectrum disorder (NMOSD) in China: a national population-based study","volume":"2","author":"Tian","year":"2020","journal-title":"Lancet Reg Health West Pac"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"959469","DOI":"10.3389\/fimmu.2022.959469","article-title":"The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e14811","DOI":"10.1111\/cns.14811","article-title":"Blood-based inflammatory protein biomarker panel for the prediction of relapse and severity in patients with neuromyelitis optica spectrum disorder: a prospective cohort study","volume":"30","author":"Wei","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1161\/atvbaha.108.183442","article-title":"Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity","volume":"29","author":"Wilhelm","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/wnl.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis Optica Spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.3389\/fneur.2019.01230","article-title":"Triglyceride level is an independent risk factor in first-attacked Neuromyelitis Optica Spectrum disorders patients","volume":"10","author":"Wu","year":"2019","journal-title":"Front. Neurol."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e626","DOI":"10.1212\/nxi.0000000000000626","article-title":"Classifying the antibody-negative NMO syndromes: clinical, imaging, and metabolomic modeling","volume":"6","author":"Yeo","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2025.1629357\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T05:25:09Z","timestamp":1752557109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2025.1629357\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":29,"alternative-id":["10.3389\/fnins.2025.1629357"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2025.1629357","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"article-number":"1629357"}}